OmniScience had a strong presence at SCOPE 2026. CEO Angela Holmes presented Vivo on the VIP stage and shared operational lessons from a Vivo pilot currently underway in a rare disease program from the Innovation Stage. These sessions spoke to development teams navigating the same challenge: too much data, too little time to act on it.

The Challenge: Data Without Intelligence

Clinical trials today generate vast volumes of data across disconnected systems—EDC, labs, imaging, safety platforms, CTMS, COAs, and more. The result is a fragmented picture that teams are expected to act on in real time, using tools designed for a different era.

Angela’s VIP presentation put the problem plainly: teams are still relying on spreadsheets, limited system access, and custom analyses to gain visibility into their trials. Critical questions go unanswered. Operational risks accumulate. And by the time a periodic review surfaces an issue, the window to intervene has often passed.

Vivo: Real-Time AI Control Tower for Clinical Trials

Vivo unifies data from all trial sources (EDC, CTMS, labs, safety, imaging, COAs) into one AI-ready environment.

Using agentic AI, it acts as a cognitive partner, continuously interpreting evidence, surfacing signals, and enabling fast decisions. Teams get consolidated, near real-time dashboards for enrollment, safety, data integrity, and operational risk. Ask Vivo allows conversational data interaction for immediate answers.

Agentic AI monitors trials, automatically alerting teams to safety trends, protocol deviations, enrollment risks, and data anomalies, enabling earlier intervention.

AI in Practice: Lessons from an Active Pilot

The Innovation Stage session gave SCOPE attendees a look inside an active Vivo deployment. OmniScience was joined by the Executive Director of Clinical Operations from a pharma company running Vivo in a pediatric rare disease open-label extension study in a high-stakes environment where data precision, early risk detection, and patient safety are paramount.

The deployment moved quickly. In eight weeks, the team completed legal review, unified their trial data, and went live with Vivo. Within four months, Vivo had become central to daily operations used actively by teams across executive leadership, clinical operations, medical monitoring, and data management.

Ask Vivo saw particularly strong adoption with teams asking hundreds of questions spanning protocol deviations, adverse events, dosing, labs, imaging, and risk metrics. In live meetings, Ask Vivo responses frequently replaced follow-up action items with immediate answers.

The outcome: insight generation accelerated, manual effort decreased, and the team’s ability to stay ahead of emerging risks improved meaningfully across the study.

“We have run many AI pilots and been disappointed. Vivo is a shining star.” - BioPharma Clinical Executive

Knowing Early Changes the Outcome

The central message from SCOPE wasn’t simply that AI can answer questions faster. It’s that when data is unified accurately and intelligence operates continuously, clinical development teams can detect risk earlier, while there is still time to change the outcome.

This aligns directly with where the industry is heading. As the FDA’s One Trial initiative and broader regulatory modernization push clinical development toward real-time evidence review and AI-ready trial data, the ability to continuously interpret trial data goes from being operationally valuable to foundational.

As Angela noted on stage: “We built Vivo so teams can know early when risks are emerging, when milestones are at risk, and when unexpected behavior occurs—so they can change the outcome.”

In an industry where patients are waiting for new therapies, the shift from delayed insight to real-time intelligence makes all the difference. That’s the work we’re doing at OmniScience and what we were proud to bring to SCOPE 2026.